Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

@inproceedings{MadozGrpide2015ActivationOM,
  title={Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer},
  author={Juan Madoz-G{\'u}rpide and Sandra Zazo and Cristina Chamizo and Victoria Casado and Cristina Caram{\'e}s and Eduardo Gav{\'i}n and Ion Crist{\'o}bal and Jes{\'u}s Miguel Garc{\'i}a-Foncillas and Federico Cuesta Rojo},
  booktitle={Journal of Translational Medicine},
  year={2015}
}
Activation of the MET oncogene promotes tumor growth, invasion and metastasis in several tumor types. Additionally, MET is activated as a compensatory pathway in the presence of EGFR blockade, thus resulting in a mechanism of resistance to EGFR inhibitors. We have investigated the impact of HGF and MET expression, MET activation (phosphorylation), MET gene status, and MET-activating mutations on cetuximab sensitivity in recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC… CONTINUE READING
Highly Cited
This paper has 22 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Cancer statistics, 2013.

CA: a cancer journal for clinicians • 2013

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 1 Excerpt

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 2 Excerpts